BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27314512)

  • 1. Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease.
    Gonçalves SA; Outeiro TF
    Small GTPases; 2017 Apr; 8(2):78-84. PubMed ID: 27314512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity.
    Gonçalves SA; Macedo D; Raquel H; Simões PD; Giorgini F; Ramalho JS; Barral DC; Ferreira Moita L; Outeiro TF
    PLoS Genet; 2016 Apr; 12(4):e1005995. PubMed ID: 27123591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
    Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
    PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
    Svarcbahs R; Julku UH; Myöhänen TT
    J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity.
    Chutna O; Gonçalves S; Villar-Piqué A; Guerreiro P; Marijanovic Z; Mendes T; Ramalho J; Emmanouilidou E; Ventura S; Klucken J; Barral DC; Giorgini F; Vekrellis K; Outeiro TF
    Hum Mol Genet; 2014 Dec; 23(25):6732-45. PubMed ID: 25092884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
    Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
    Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
    Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
    Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental and genetic factors support the dissociation between α-synuclein aggregation and toxicity.
    Villar-Piqué A; Lopes da Fonseca T; Sant'Anna R; Szegö ÉM; Fonseca-Ornelas L; Pinho R; Carija A; Gerhardt E; Masaracchia C; Abad Gonzalez E; Rossetti G; Carloni P; Fernández CO; Foguel D; Milosevic I; Zweckstetter M; Ventura S; Outeiro TF
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6506-E6515. PubMed ID: 27708160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.
    Zondler L; Miller-Fleming L; Repici M; Gonçalves S; Tenreiro S; Rosado-Ramos R; Betzer C; Straatman KR; Jensen PH; Giorgini F; Outeiro TF
    Cell Death Dis; 2014 Jul; 5(7):e1350. PubMed ID: 25058424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
    Dominguez-Meijide A; Vasili E; König A; Cima-Omori MS; Ibáñez de Opakua A; Leonov A; Ryazanov S; Zweckstetter M; Griesinger C; Outeiro TF
    Sci Rep; 2020 Jul; 10(1):12827. PubMed ID: 32732936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.
    Masaracchia C; König A; Valiente-Gabioud AA; Peralta P; Favretto F; Strohäker T; Lázaro DF; Zweckstetter M; Fernandez CO; Outeiro TF
    Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140298. PubMed ID: 31676453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease.
    Tenreiro S; Reimão-Pinto MM; Antas P; Rino J; Wawrzycka D; Macedo D; Rosado-Ramos R; Amen T; Waiss M; Magalhães F; Gomes A; Santos CN; Kaganovich D; Outeiro TF
    PLoS Genet; 2014 May; 10(5):e1004302. PubMed ID: 24810576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
    Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
    Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane binding, internalization, and sorting of alpha-synuclein in the cell.
    Masaracchia C; Hnida M; Gerhardt E; Lopes da Fonseca T; Villar-Pique A; Branco T; Stahlberg MA; Dean C; Fernández CO; Milosevic I; Outeiro TF
    Acta Neuropathol Commun; 2018 Aug; 6(1):79. PubMed ID: 30107856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
    Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
    J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose.
    Hoffmann AC; Minakaki G; Menges S; Salvi R; Savitskiy S; Kazman A; Vicente Miranda H; Mielenz D; Klucken J; Winkler J; Xiang W
    Sci Rep; 2019 Jan; 9(1):544. PubMed ID: 30679445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
    Wales P; Pinho R; Lázaro DF; Outeiro TF
    J Parkinsons Dis; 2013; 3(4):415-59. PubMed ID: 24270242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity.
    Ferreira DG; Batalha VL; Vicente Miranda H; Coelho JE; Gomes R; Gonçalves FQ; Real JI; Rino J; Albino-Teixeira A; Cunha RA; Outeiro TF; Lopes LV
    Cereb Cortex; 2017 Jan; 27(1):718-730. PubMed ID: 26534909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response.
    Delaidelli A; Richner M; Jiang L; van der Laan A; Bergholdt Jul Christiansen I; Ferreira N; Nyengaard JR; Vægter CB; Jensen PH; Mackenzie IR; Sorensen PH; Jan A
    Acta Neuropathol Commun; 2021 Jun; 9(1):105. PubMed ID: 34092244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.